Brooke Linney, Brigham Young University
Life Sciences
Recombinant DNA technology has become one of the most critical fields of research relating to biotechnology. Recombinant DNA can be used to obtain certain proteins or examine the effects of genes that we engineer, with many applications in medical research. As part of our lab’s use for recombinant DNA, we create a gene sequence to code for a certain protein, and then use heat-shocking transformation to stimulate Escherichia coli bacterial cells to incorporate the mutated DNA from the surrounding solution. As the bacterial cells then grow, they replicate the mutated plasmid that we introduced. This DNA can later be extracted from the bacterial cells and used for further synthesis, usually protein synthesis in our lab. The process of transforming bacterial cells with mutated DNA is directly affected by plasmid size. Transformation efficiency is maximized with smaller plasmids. One of the DNA plasmids we use to introduce mutations is the pET9a vector. This plasmid is a sequence of 4,341 base pairs, but by reducing the length of the plasmid, we can increase transformation efficiency. By restricting the size of the pET9a vector, we will also be able to introduce larger foreign DNA sequences than we would with the original pET9a vector. This presentation will explore the different methods of reducing sequence length to optimize the pET9a vector, mainly focusing on site-directed mutagenesis coupled with the use of restriction enzymes.